Atherosclerosis regression: is low-density lipoprotein or high-density lipoprotein the answer?

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Medical Imaging

Background:

• Lowering low-density lipoprotein cholesterol (LDL-C) is crucial for managing coronary artery disease (CAD).
• Developing therapies to enhance high-density lipoprotein (HDL) biologic activity is a growing focus.
• Artery wall imaging allows evaluation of medical therapies' effects on plaque burden.

Purpose of the Study:

• To review the current evidence on the impact of plasma lipid changes on plaque regression.
• To assess the role of LDL-C lowering and HDL-promoting agents in CAD risk modification.

Main Methods:

• Review of existing scientific literature and clinical reports.
• Analysis of studies evaluating lipid-modifying interventions.
• Examination of data from artery wall imaging studies.

Main Results:

• Interventions targeting LDL-C reduction show favorable effects on plaque burden.
• Agents promoting HDL biologic activity also demonstrate beneficial impacts.
• Evidence links plasma lipid profile shifts to the potential for plaque regression.

Conclusions:

• Lipid modification strategies, particularly LDL-C lowering, are central to CAD risk management.
• Further research into HDL-focused therapies and their effect on plaque regression is warranted.
• Artery wall imaging provides valuable insights into therapeutic efficacy for CAD.